These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 30723112)
1. Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112 [TBL] [Abstract][Full Text] [Related]
2. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727 [TBL] [Abstract][Full Text] [Related]
3. Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System. DO J; Yenwongfai LN; DO SI; Kim SW; Na K Anticancer Res; 2024 Jul; 44(7):2953-2960. PubMed ID: 38925823 [TBL] [Abstract][Full Text] [Related]
4. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies. Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic correlates of Sethi TK; Kovach AE; Grover NS; Huang LC; Lee LA; Rubinstein SM; Wang Y; Morgan DS; Greer JP; Park SI; Ann Thompson-Arildsen M; Yenamandra A; Vnencak-Jones CL; Reddy NM Leuk Lymphoma; 2019 Dec; 60(12):2880-2889. PubMed ID: 31184237 [TBL] [Abstract][Full Text] [Related]
6. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Gonzalez-Aguilar A; Idbaih A; Boisselier B; Habbita N; Rossetto M; Laurenge A; Bruno A; Jouvet A; Polivka M; Adam C; Figarella-Branger D; Miquel C; Vital A; Ghesquières H; Gressin R; Delwail V; Taillandier L; Chinot O; Soubeyran P; Gyan E; Choquet S; Houillier C; Soussain C; Tanguy ML; Marie Y; Mokhtari K; Hoang-Xuan K Clin Cancer Res; 2012 Oct; 18(19):5203-11. PubMed ID: 22837180 [TBL] [Abstract][Full Text] [Related]
7. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma. Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383 [TBL] [Abstract][Full Text] [Related]
8. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. Hattori K; Sakata-Yanagimoto M; Kusakabe M; Nanmoku T; Suehara Y; Matsuoka R; Noguchi M; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Muratani M; Hasegawa Y; Chiba S Cancer Sci; 2019 Jan; 110(1):401-407. PubMed ID: 30353605 [TBL] [Abstract][Full Text] [Related]
9. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068 [TBL] [Abstract][Full Text] [Related]
10. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087 [TBL] [Abstract][Full Text] [Related]
11. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Cobbers JM; Wolter M; Reifenberger J; Ring GU; Jessen F; An HX; Niederacher D; Schmidt EE; Ichimura K; Floeth F; Kirsch L; Borchard F; Louis DN; Collins VP; Reifenberger G Brain Pathol; 1998 Apr; 8(2):263-76. PubMed ID: 9546285 [TBL] [Abstract][Full Text] [Related]
12. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma. Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416 [TBL] [Abstract][Full Text] [Related]
13. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Chapuy B; Roemer MG; Stewart C; Tan Y; Abo RP; Zhang L; Dunford AJ; Meredith DM; Thorner AR; Jordanova ES; Liu G; Feuerhake F; Ducar MD; Illerhaus G; Gusenleitner D; Linden EA; Sun HH; Homer H; Aono M; Pinkus GS; Ligon AH; Ligon KL; Ferry JA; Freeman GJ; van Hummelen P; Golub TR; Getz G; Rodig SJ; de Jong D; Monti S; Shipp MA Blood; 2016 Feb; 127(7):869-81. PubMed ID: 26702065 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR. Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019 [TBL] [Abstract][Full Text] [Related]
15. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Yamada S; Ishida Y; Matsuno A; Yamazaki K Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427 [TBL] [Abstract][Full Text] [Related]
16. [Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation]. Fu YL; Xue XM; Shen GH; Yuan LJ; Zheng B; Zhang HF; Qiu T; Huang WT Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):751-755. PubMed ID: 34405609 [No Abstract] [Full Text] [Related]
17. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797 [TBL] [Abstract][Full Text] [Related]
18. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744 [TBL] [Abstract][Full Text] [Related]
19. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR. Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053 [TBL] [Abstract][Full Text] [Related]
20. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]